Welcome to today’s daily blog post on stocks that I own. In this post, we will be discussing some recent events in the world of finance that could have an impact on the stock market. Let’s dive right in!
Nano Dimension to Release Q1 2023 Financial Results
Nano Dimension Ltd. (Nasdaq: NNDM), a leading provider of Additively Manufactured Electronics and multi-dimensional polymer, metal & ceramic Additive Manufacturing 3D printers, announced on June 16, 2023, that it will be releasing its financial results for the first quarter of 2023 before the Nasdaq market opens on Thursday, June 29th, 2023. The release will be followed by a conference call hosted by the Chairman and CEO, Mr. Yoav Stern, CFO, Ms. Yael Sandler, and VP Corporate Development, Mr. Julien Lederman. Interested parties can register for the conference via the company’s website with the dial-in numbers provided for participants.
The press release did not include any information about the expected financial performance of the company for the quarter. However, shareholders will be eagerly anticipating the release to get an insight into the company’s performance.
Nano Dimension’s core business is in providing 3D printing electronics solutions. The company’s multi-layer 3D printer, the DragonFly LDM, is known for producing printed circuit boards effectively and efficiently, among other things. The company’s Additively Manufactured Electronics technology has vast capabilities in sensitive electronics processes even in complex geometries hence serving the consumer electronics, aerospace, defense, medical, and automotive industries.
My personal thoughts as an investor in Nano Dimension are that the upcoming financial results will be crucial in determining the future of the company. Positive results could mean an increase in the company’s share price and a potential buying opportunity for the investors. However, investors should be vigilant and watch the market trend before making any decisions. If the news is negative, it might be wise to consider selling the stock.
Furthermore, the announcement about the 2023 Annual Meeting of Stockholders is a significant development for the company. Shareholders will have the opportunity to participate in the decision-making process and voice their opinions about the company’s future direction.
In summary, the upcoming release of Nano Dimension’s Q1 2023 financial results and its 2023 Annual Meeting of Stockholders are essential developments that could impact the future of this company. As an investor, it will be crucial to keep an eye out for the results and remain vigilant in making the right investment decisions.
ACELYRIN Reports Strong Financial Results and Accelerated Clinical Milestones
ACELRYN (Nasdaq: SLRN), a late-stage clinical biopharma company, recently reported strong financial results for the first quarter ended on March 31, 2023, and announced significant progress in its research and development initiatives aimed at addressing autoimmune and inflammatory diseases.
The company generated gross proceeds of $621 million and has a strong cash position of $289.2 million at the end of Q1 2023, which is expected to fund key milestones across all three clinical programs. At present, ACELYRIN is actively enrolling patients for two clinical trials, namely, Lonigutamab and SLRN-517, in Phase 1/2 proof-of-concept studies.
The company is pleased to announce that the P2b/3 randomized controlled study of izokibep in Hidradenitis Suppurativa (HS) is anticipated to yield accelerated top-line data in Q3 2023, ahead of schedule. In addition, the company has initiated a second confirmatory HS P3 trial and is actively enrolling patients.
ACELRYN’s future looks promising, and I highly recommend buying the stock. Its ongoing clinical trials have tremendous potential to address unmet medical needs in the field of immunology. With a strong cash position, the company can focus on driving key value-driving milestones to deliver on their development plans efficiently. The acceleration of the pivotal data for izokibep in HS is a significant achievement that reflects the company’s exceptional research and development capabilities. ACELYRIN is a stock to watch closely, and I am optimistic about its future prospects.
Mullen Automotive Provides A Business Update Letter To Shareholders Amidst 90% Share Price Drop
Mullen Automotive, Inc. (NASDAQ: MULN) is an emerging electric vehicle manufacturer based in BREA, California. The company recently provided a business update letter to its shareholders in response to the decrease in share price which has fallen 90% from $3.25 per share since March 31, 2023, closing at $0.32 per share on June 13, 2023. The letter explains that the company’s current stock value trades at a discount to its current cash position of $135 million or $0.38 per share.
Despite the decrease in share price, Mullen automotive states that it is in position to meet the previously announced objectives for moving first into the production and then sale of their Class 3 commercial vehicles during the quarter ending Sept. 30, 2023. The company also reported cash available to operations amounting to $86.7 million and book value per share of $2.08 as of March 31, 2023.
Moreover, according to the letter, the company has completed two major acquisitions that add valuable unencumbered assets to their balance sheet. The first acquisition was Bollinger Motors on September 7, 2022, for $148 million, including $77 million to fund all vehicle development, manufacturing, and capital needs to launch the class 4 EV chassis cab truck (Bollinger B4). The second acquisition was Electric Last Mile Solutions (“ELMS”) for $105 million on December 1, 2022, which included all of the IP and a 650,000-square-foot manufacturing plant in Mishawaka, Indiana.
Personally, I am concerned about Mullen Automotive’s current stock value, which is trading at a 90% share price drop since March 31, 2023. The letter portrays a positive outlook for the company’s future, with them being prepared to meet their objectives alongside two major acquisitions that add value to their balance sheet. However, this doesn’t change the fact that the current stock value is trading well below its book value. Therefore, while the news is not entirely negative, it is still not convincing enough for me. Based on the information provided, I recommend selling the stock until there is a clearer indication of the company’s growth prospects.
Rafael Holdings Reports Third Quarter Fiscal Year 2023 Financial Results
Rafael Holdings, a holding company with interests in pharmaceuticals, real estate, and technology, has reported their financial results for the third quarter of fiscal year 2023. The company reported a net loss from continuing operations of $1.5 million, or $0.06 per share, for the three months ended April 30, 2023. This is an improvement from the same period in the prior year, where the company had reported a net loss from continuing operations of $5.0 million, or $0.25 per share. The company attributes this to a decrease in research and development expenses due to the winding down of early-stage programs.
Moreover, the company is making strategic investments in companies with near term value inflection points to expand its portfolio. Recently, Rafael Holdings made a follow-on strategic investment in Cyclo Therapeutics, in support of a Phase 3 registrational clinical trial for patients with Niemann-Pick Disease Type C. Cyclo Therapeutics is a biotechnology company that focuses on the development of cyclodextrin-based products for the treatment of rare and serious diseases.
As a long-term investor in Rafael Holdings, I see the potential value that the company can generate for its shareholders through strategic investments. I am pleased to see the decrease in net loss from continuing operations and the company’s commitment to expand its portfolio. Based on these positive developments, I recommend holding the stock. However, I will continue to monitor the company’s progress closely.
NIO Inc. Announces Q1 2023 Financial Results: Revenues Increase, Deliveries Decrease
NIO, a pioneer in the premium smart electric vehicle market, reported their unaudited financial results for the first quarter ended March 31, 2023. The company generated RMB10,676.5 million (US$1,554.6 million) in total revenues, a 7.7% increase from Q1 2022, and delivered 31,041 vehicles, consisting of 10,430 SUVs and 20,611 sedans.
While the revenues increased, there was a decrease of 22.5% in vehicle deliveries from Q4 2022. Additionally, the vehicle margin decreased to 5.1% from 18.1% in Q1 2022, and the company recorded a gross profit of only RMB162.3 million (US$23.6 million), a decrease of 88.8% from Q1 2022.
The significant decrease in gross profit and margin is concerning, and it’s important to see how NIO plans to address this in future quarters. The decrease in vehicle deliveries may be attributed to the ongoing global chip shortage affecting the automotive industry.
However, NIO’s commitment to innovation and sustainability in the electric vehicle market is encouraging. The company continues to expand its network of battery-swapping stations, and its luxury electric sedan, the ET7, has generated a lot of buzz.
Overall, while the financial results for Q1 2023 are not entirely positive, I believe NIO has a strong foundation in the electric vehicle market and is well-positioned to remain a key player in the industry. For individuals who already own the stock, I recommend holding for now and keeping an eye on future announcements. For those considering investing, it may be wise to wait for more clarity on the chip shortage and the company’s plans to address decreasing margins and profits.